Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 5c

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) reported Q2 EPS of ($0.97), $0.05 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Kyverna Therapeutics, Inc. (KYTX) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
• Yamazaki Baking (2212:JP) PT Lowered to JPY4,100 at UBS
• UBS Upgrades Zhejiang Leapmotor Technology (9863:HK) to Buy